Bexarotene / Bexaroteno 75mg
Product Overview
| Generic Name | Bexarotene / Bexaroteno 75mg |
| Brand Name(s) | Targretin® |
| Category | Antineoplastic / Cancer |
| Form | 100 Oral liquid-filled soft gelatin capsules |
| Strength | 75 mg |
| Therapeutic Class | Antineoplastic retinoid; retinoid X receptor agonist / RXR-selective retinoid |
| ATC Code | L01XF03 |
Manufacturing & Regulatory
| Manufacturer | HAC, Actavis |
| GMP Compliance | WHO-GMP |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 5 bottles / 500 caps |
| Shelf Life | 24 Months |
| Storage | 2°C to 25°C / 36°F to 77°F |
| Incoterms | EXW / FCA mfg /distributor warehouse |
| Lead Time | 7–14 business days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | Upon Request, not publicly posted |
| CTD Summary (PDF) | CTD proprietary; available under commercial agreement/license |
Special Notes
Bexarotene is a retinoid antineoplastic used for cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients refractory to at least one prior systemic therapy.